title: Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.
abstract: Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for management of CINV in patients receiving multiple-day chemotherapy regimens. Serotonin (5-HT3) receptor antagonists are a mainstay in preventing CINV, and palonosetron, given its longer half-life and duration of action relative to other 5-HT3 receptor antagonists, may be a useful option for managing CINV in multiple-day chemotherapy. Here we provide an overview of CINV and CINV treatment options, with a focus on palonosetron. We describe existing challenges in managing CINV, and discuss two patients receiving multiple-day chemotherapy, in whom CINV was managed successfully with palonosetron.
authors.affiliation: Duke University Medical Center, Durham, NC, USA.
authors.forename: Mary Lou
authors.initials: ML
authors.lastname: Affronti
authors.affiliation: Oregon Health and Science University Hospital and Clinics, Portland, OR, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Bubalo
keywords: 5-HT3 receptor antagonist; chemotherapy-induced nausea and vomiting; multiple-day chemotherapy; palonosetron